sector medic suppli devic
 shine fx reinvest cap
messag sale top consensu ep fell short
street driven fx increas opex revenu beat driven larg
cc saw growth acceler vs amid continu contact
len market strength howev top line upsid like partial overshadow
reduc earn power expect street ep project beyond
move lower back thursday report share fulli valu current
level rel revis estim view maintain neutral rate
mix quarter reduc earn power partial overshadow revenu upsid
revenu pro forma top consensu adjust
ep yoy came shi street expect drove bulk
top line out-performance growth acceler sequenti pro forma
meanwhil manag larg blame currenc earn shortfal fx come
unfavor rel forecast spend also ran ahead street expect
howev ebita margin miss consensu forecast
elsewher lower expect tax rate ad earn
tougher currenc environ heighten expens level like persist
next quarter fx set swing headwind ceo al white indic
compani see near-term opportun invest support futur growth
mind manag lower ep guidanc midpoint
exclud currenc accret paragard deal
estim revis outlook impli underli ep growth year
look ahead expect street ep estim move lower well
give formal guidanc decemb thursday call cfo brian
andrew note compani focus drive strong revenu growth low
double-digit constant currenc oper incom growth although view manag
confid sustain current top line momentum encourag
implic outlook next year bottom line less posit layer fx
headwind math higher tax rate vs estim
earn like grow mid-single-digit clip next year model
call adjust ep vs current consensu
turn back quarter coopervis sale pro forma came
consensu underli revenu came
estim currenc modestli bigger top line tailwind forecast
categori perspect upsid driven primarili out-performance single-us
sphere cc multifoc cc came
street respect elsewher toric cc line
street expect non single-us sphere cc came shi
consensu geograph standpoint three segment acceler sequenti
strength america cc asia pacif cc boost slower growth
emea cc estim silicon hydrogel len sale rose
forecast continu strength daili sih franchis
cc partial off-set on-going avaira weak franchis transit new
avaira vital brand overal extend wear sih sale rose cc biofin continu
post solid gain offset modest declin avaira vital transit
wrap quarter manag lower revenu guidanc
driven reduc fx tailwind underli growth
expect stay rang howev strong momentum
contact len market broadli remain tailwind major player
continu page
page analyst certif import disclosur
estim global contact len sale rose cc calendar
acceler sequenti cooper share rose vs calendar
compar also saw strong gain quarter sequenti
yoy bausch continu recent resurg sequenti yoy
alcon cede ground sequenti yoy overal contact
len market healthi time margin out-performance
continu narrow differ trail twelv month underli
growth rate three largest competitor smallest level year
see figur manag believ compress larg due competitor
increas success drive trade-up within instal base dynam result
improv dollar share without actual gain patient level may part
stori sens competit environ also tougher
time remain expect product launch alcon
bausch next quarter thursday call mr white downplay idea
challeng competit backdrop behind compani decis invest
aggress promot advertis activ aim drive increas new
fit share worth note maintain consist strong growth
past coupl year even peer improv perform howev
longtim posit share taker lens seemingli jeopardi
first time decad see figur expect investor concern
increas competit remain front mind
compani report guggenheim secur llc estim
compani report guggenheim secur llc estim
turn coopersurg revenu pro forma top
consensu paragard strong quarter sale came
higher forecast despit two straight quarter trend perform
sale rose howev manag expect paragard growth slow
mid-singl digit clip go forward financi impact paragard readili appar
quarter csi gross margin jump yoy elsewher
underli offic surgic product busi pro forma fertil
segment pro forma acceler sequenti full year manag
forecast csi sale previous impli
underli grow fourth quarter
page analyst certif import disclosur
top line higher spend reduc fx tailwind prevent revenu
beat flow earn fiscal gross margin
yoy consensu sg spend rose yoy
sale came street expect meanwhil spend grew
yoy sale higher consensu collect result fiscal
ebita margin yoy street estim
bottom line adjust ep came consensu
manag larg chalk shortfal strong dollar currenc
unfavor rel rate time call would note impact
off-set lower expect tax rate vs consensu
ad quarter meanwhil oper expens grown
faster sale five past seven quarter reach level
manag signal increas invest like continu
least next quarter moder forecast increment margin
expect investor pleas anoth quarter strong top line
growth believ reduc earn power limit stock upsid potenti
model call ep total revenu
pro forma compar prior forecast
respect meanwhil lower ep project
take account recent currenc fluctuat higher assum spend level go
forward base thursday close price share trade revis
ntm ep estim premium large-cap med-tech averag
cooper superior top line growth rate vs large-cap group would seem
argu premium valuat dont see compani sustain bottom line
growth trajectori meaning differenti group averag also
view outsiz exposur currenc swing rise interest rate
consum categori believ could prove highli cyclic next econom
downturn argument multipl expans result maintain
page analyst certif import disclosur
straddl line healthcar consum product contact
len women health busi coopervis portfolio uniqu posit take
advantag two tailwind drive contact len market growth today shift
premium len materi particular silicon hydrogel increas popular
daili dispos lens recent year leverag broadest daili sih
offer market lead posit monthli sih categori continu
long histori above-market growth compani captur averag
market share per year sinc expect gain moder go forward
backdrop competit contact len market believ cooper
remain well posit sustain growth
elsewher paragard deal add scale coopersurg grow women health
presenc often overlook investor expect csi account
overal revenu growth fuel
primarili compani invest half dozen deal
build lead posit ivf genet test market follow recent
acquisit paragard intrauterin devic believ long-term
fundament market appeal see grow scale csi neg
broader invest case complic stori believ
investor would prefer look sole contact len play
share current trade ntm ep ntm ebitda
repres premium large-cap med-tech group averag price-to-earnings
ev/ebitda basi superior top line growth rate vs
large-cap group would seem argu premium valuat dont see
compani sustain bottom line growth trajectori meaning differenti
group averag also view cooper outsiz exposur currenc swing
rise interest rate consum categori believ could prove highli
cyclic next econom downturn argument multipl expans
result maintain neutral rate
upsid risk rate includ faster expect contact len market growth due
rise sih penetr daili len adopt increas share gain
busi better expect growth/accret paragard
downsid risk rate includ better anticip traction competit
contact len launch weaken macroeconom backdrop put pressur
cooper busi see discretionari med-tech market
potenti exposur strong dollar rise interest rate
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
compani report guggenheim secur llc estim
page analyst certif import disclosur
